PharmaCorp Rx (TSXV:PCRX) Beneish M-Score: -1.18 (As of Jun. 26, 2026)


TSXV:PCRX PharmaCorp Rx Inc TSXV:PCRX
33 GF Score
Price C$0.52
! 2 Warning Signs
View Full Analysis

What is PharmaCorp Rx Beneish M-Score?

PharmaCorp Rx TSXV:PCRX +1.96% 33 Beneish M-Score is -1.18 as of Jun. 26, 2026. GuruFocus rates TSXV:PCRX with a GF Score™ of 33/100. The stock has 2 warning signs investors should review. Among 633 Healthcare Providers & Services companies, PharmaCorp Rx ranks worse than 91% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score -1.18 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for PharmaCorp Rx's Beneish M-Score or its related term are showing as below:

TSXV:PCRX' s Beneish M-Score Range Over the Past 10 Years
Min: -1.18   Med: 3.61   Max: 41.43
Current: -1.18

During the past 5 years, the highest Beneish M-Score of PharmaCorp Rx was 41.43. The lowest was -1.18. And the median was 3.61.


PharmaCorp Rx Beneish M-Score Historical Data

* Premium members only.

The historical data trend for PharmaCorp Rx's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PharmaCorp Rx Beneish M-Score Chart

PharmaCorp Rx Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
0.00 0.00 0.00 0.00 -0.79

PharmaCorp Rx Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 41.43 8.00 -0.79 -1.18

PharmaCorp Rx Beneish M-Score Competitor Comparison

For the Pharmaceutical Retailers subindustry, PharmaCorp Rx's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PharmaCorp Rx Beneish M-Score vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, PharmaCorp Rx's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where PharmaCorp Rx's Beneish M-Score falls into.


TSXV:PCRX
33GF Score
PharmaCorp Rx Inc TSXV:PCRX
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PharmaCorp Rx Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of PharmaCorp Rx for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.2968+0.528 * 0.9882+0.404 * 1.0211+0.892 * 2.4565+0.115 * 0.6322
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9005+4.679 * -0.015634-0.327 * 1.5382
=-1.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was C$1.19 Mil.
Revenue was 7.188 + 7.69 + 4.802 + 4.396 = C$24.08 Mil.
Gross Profit was 2.792 + 2.967 + 1.959 + 1.748 = C$9.47 Mil.
Total Current Assets was C$27.71 Mil.
Total Assets was C$63.13 Mil.
Property, Plant and Equipment(Net PPE) was C$5.44 Mil.
Depreciation, Depletion and Amortization(DDA) was C$1.11 Mil.
Selling, General, & Admin. Expense(SGA) was C$9.88 Mil.
Total Current Liabilities was C$2.94 Mil.
Long-Term Debt & Capital Lease Obligation was C$3.94 Mil.
Net Income was 0.108 + -0.852 + -0.428 + -0.384 = C$-1.56 Mil.
Non Operating Income was 0.061 + 0.097 + 0.034 + 0.033 = C$0.23 Mil.
Cash Flow from Operations was -2.67 + 1.513 + 0.55 + -0.187 = C$-0.79 Mil.
Total Receivables was C$0.37 Mil.
Revenue was 4.007 + 4.399 + 1.104 + 0.291 = C$9.80 Mil.
Gross Profit was 1.624 + 1.67 + 0.415 + 0.099 = C$3.81 Mil.
Total Current Assets was C$14.97 Mil.
Total Assets was C$35.44 Mil.
Property, Plant and Equipment(Net PPE) was C$3.99 Mil.
Depreciation, Depletion and Amortization(DDA) was C$0.48 Mil.
Selling, General, & Admin. Expense(SGA) was C$4.47 Mil.
Total Current Liabilities was C$1.74 Mil.
Long-Term Debt & Capital Lease Obligation was C$0.77 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(1.185 / 24.076) / (0.372 / 9.801)
=0.049219 / 0.037955
=1.2968

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(3.808 / 9.801) / (9.466 / 24.076)
=0.388532 / 0.393172
=0.9882

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (27.712 + 5.44) / 63.132) / (1 - (14.965 + 3.992) / 35.439)
=0.474878 / 0.465081
=1.0211

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=24.076 / 9.801
=2.4565

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.477 / (0.477 + 3.992)) / (1.105 / (1.105 + 5.44))
=0.106735 / 0.168831
=0.6322

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(9.877 / 24.076) / (4.465 / 9.801)
=0.410243 / 0.455566
=0.9005

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((3.936 + 2.942) / 63.132) / ((0.766 + 1.744) / 35.439)
=0.108946 / 0.070826
=1.5382

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-1.556 - 0.225 - -0.794) / 63.132
=-0.015634

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

PharmaCorp Rx has a M-score of -1.18 signals that the company is likely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -1.18 mean?
PharmaCorp Rx (TSXV:PCRX) has a Beneish M-Score of -1.18 as of Jun. 26, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on PharmaCorp Rx and its competitors. According to the industry distribution chart, PharmaCorp Rx ranks #576 out of 633 companies in the Healthcare Providers & Services industry, placing it in the top 91%.
Is PharmaCorp Rx's Beneish M-Score too high?
PharmaCorp Rx's current Beneish M-Score is -1.18. Based on the distribution chart, PharmaCorp Rx ranks #576 out of 633 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, PharmaCorp Rx has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does PharmaCorp Rx's Beneish M-Score compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, PharmaCorp Rx ranks #576 out of 633 companies for Beneish M-Score. This places PharmaCorp Rx in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Healthcare Providers & Services company?
A good Beneish M-Score depends on the Healthcare Providers & Services industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on PharmaCorp Rx and its competitors. PharmaCorp Rx's current Beneish M-Score is -1.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaCorp Rx stock overvalued right now?
PharmaCorp Rx (TSXV:PCRX) has a current Beneish M-Score of -1.18. The current Beneish M-Score is -1.18. PharmaCorp Rx's overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For PharmaCorp Rx (TSXV:PCRX), the current Beneish M-Score is -1.18 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PharmaCorp Rx Business Description

Address 303 Wellman Lane, Suite 203, Saskatoon, SK, CAN, S7T 0J1
PharmaCorp Rx Inc operates three PharmaChoice bannered pharmacies in Canada and will continue to acquire PharmaChoice Canada-branded pharmacies as it come to market in conjunction with its strategic alliance agreement with PharmaChoice Canada. The company will also acquire independently owned non-PharmaChoice Canada-bannered pharmacies in Canada, and thereafter, continue to operate such acquired pharmacies under a PharmaChoice Canada banner.
33GF Score

Get the complete analysis for TSXV:PCRX

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$0.52
Price